The announcement that Omega has agreed a manufacturing contract with the UK Government to produce lateral flow antigen tests, as part of its plans to control the spread of the coronavirus, is a significant endorsement of Omega’s capabilities and competencies, as the government seemingly seeks to ensure the security of supply of such tests from within the UK. We have adjusted FY 2021 forecasts downwards to reflect the concomitant trading update, which highlights a c.£3.3m shortfall in revenues, l ....
